Literature DB >> 28535000

Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.

Onofrio Antonio Catalano1, Dania Daye1, Alberto Signore2, Carlo Iannace3, Mark Vangel4, Angelo Luongo5, Marco Catalano6, Mazzeo Filomena7, Luigi Mansi8, Andrea Soricelli9, Marco Salvatore10, Niccolo Fuin4, Ciprian Catana4, Umar Mahmood1, Bruce Robert Rosen4.   

Abstract

The aim of the present study was to evaluate the performance of whole-body diffusion-weighted imaging (WB-DWI), whole-body positron emission tomography with computed tomography (WB-PET/CT), and whole-body positron emission tomography with magnetic resonance imaging (WB-PET/MRI) in staging patients with untreated invasive ductal carcinoma of the breast. Fifty-one women with newly diagnosed invasive ductal carcinoma of the breast underwent WB-DWI, WB-PET/CT and WB-PET/MRI before treatment. A radiologist and a nuclear medicine physician reviewed in consensus the images from the three modalities and searched for occurrence, number and location of metastases. Final staging, according to each technique, was compared. Pathology and imaging follow-up were used as the reference. WB-DWI, WB-PET/CT and WB-PET/MRI correctly and concordantly staged 33/51 patients: stage IIA in 7 patients, stage IIB in 8 patients, stage IIIC in 4 patients and stage IV in 14 patients. WB-DWI, WB-PET/CT and WB-PET/MRI incorrectly and concordantly staged 1/51 patient as stage IV instead of IIIA. Discordant staging was reported in 17/51 patients. WB-PET/MRI resulted in improved staging when compared to WB-PET/CT (50 correctly staged on WB-PET/MRI vs. 38 correctly staged on WB-PET/CT; McNemar's test; p<0.01). Comparing the performance of WB-PET/MRI and WB-DWI (43 correct) did not reveal a statistically significant difference (McNemar test, p=0.14). WB-PET/MRI is more accurate in the initial staging of breast cancer than WB-DWI and WB-PET/CT, however, the discrepancies between WB-PET/MRI and WB-DWI were not statistically significant. When available, WB-PET/MRI should be considered for staging patient with invasive ductal breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28535000     DOI: 10.3892/ijo.2017.4012

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  20 in total

1.  Integrated versus separate reading of F-18 FDG-PET/CT and MRI for abdominal malignancies - effect on staging outcomes and diagnostic confidence.

Authors:  Lisa A Min; Wouter V Vogel; Max J Lahaye; Monique Maas; Maarten L Donswijk; Erik Vegt; Miranda Kusters; Henry J Zijlmans; Katarzyna Jóźwiak; Sander Roberti; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2019-05-22       Impact factor: 5.315

2.  What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?

Authors:  Diomidis Botsikas; Ilias Bagetakos; Marlise Picarra; Ana Carolina Da Cunha Afonso Barisits; Sana Boudabbous; Xavier Montet; Giang Thanh Lam; Ismini Mainta; Anastasia Kalovidouri; Minerva Becker
Journal:  Eur Radiol       Date:  2018-09-28       Impact factor: 5.315

Review 3.  Advances in simultaneous PET/MR for imaging neuroreceptor function.

Authors:  Christin Y Sander; Hanne D Hansen; Hsiao-Ying Wey
Journal:  J Cereb Blood Flow Metab       Date:  2020-03-13       Impact factor: 6.200

4.  Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing 18F-FDG-PET/MRI.

Authors:  Julian Kirchner; Johannes Grueneisen; Ole Martin; Mark Oehmigen; Harald H Quick; Ann-Kathrin Bittner; Oliver Hoffmann; Marc Ingenwerth; Onofrio Antonio Catalano; Philipp Heusch; Christian Buchbender; Michael Forsting; Gerald Antoch; Ken Herrmann; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-28       Impact factor: 9.236

5.  Hybrid PET/MRI in major cancers: a scoping review.

Authors:  Anni Morsing; Malene Grubbe Hildebrandt; Mie Holm Vilstrup; Sara Elisabeth Wallenius; Oke Gerke; Henrik Petersen; Allan Johansen; Thomas Lund Andersen; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-02       Impact factor: 9.236

6.  PET/MRI and PET/CT Radiomics in Primary Cervical Cancer: A Pilot Study on the Correlation of Pelvic PET, MRI, and CT Derived Image Features.

Authors:  Shadi A Esfahani; Angel Torrado-Carvajal; Barbara Juarez Amorim; David Groshar; Liran Domachevsky; Hanna Bernstine; Dan Stein; Debra Gervais; Onofrio A Catalano
Journal:  Mol Imaging Biol       Date:  2021-10-07       Impact factor: 3.488

7.  Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values.

Authors:  Michiro Sasaki; Mitsuhiro Tozaki; Kazunori Kubota; Wakana Murakami; Daisuke Yotsumoto; Yasuaki Sagara; Yasuyo Ohi; Shunichi Oosako; Yoshiaki Sagara
Journal:  Jpn J Radiol       Date:  2017-11-20       Impact factor: 2.374

8.  Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.

Authors:  Mariarosaria Incoronato; Anna Maria Grimaldi; Carlo Cavaliere; Marianna Inglese; Peppino Mirabelli; Serena Monti; Umberto Ferbo; Emanuele Nicolai; Andrea Soricelli; Onofrio Antonio Catalano; Marco Aiello; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-25       Impact factor: 9.236

9.  Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study.

Authors:  Felipe S Furtado; Cristina R Ferrone; Susanna I Lee; Mark Vangel; David A Rosman; Colin Weekes; Motaz Qadan; Carlos Fernandez-Del Castillo; David P Ryan; Lawrence S Blaszkowsky; Theodore S Hong; Jeffrey W Clark; Robin Striar; David Groshar; Lina G Cañamaque; Lale Umutlu; Onofrio A Catalano
Journal:  Mol Imaging Biol       Date:  2021-01-07       Impact factor: 3.488

10.  An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.

Authors:  Jad S Husseini; Bárbara Juarez Amorim; Angel Torrado-Carvajal; Vinay Prabhu; David Groshar; Lale Umutlu; Ken Herrmann; Lina García Cañamaque; José Ramón García Garzón; William E Palmer; Pedram Heidari; Tiffany Ting-Fang Shih; Jacob Sosna; Cristina Matushita; Juliano Cerci; Marcelo Queiroz; Valdair Francisco Muglia; Marcello H Nogueira-Barbosa; Ronald J H Borra; Thomas C Kwee; Andor W J M Glaudemans; Laura Evangelista; Marco Salvatore; Alberto Cuocolo; Andrea Soricelli; Christian Herold; Andrea Laghi; Marius Mayerhoefer; Umar Mahmood; Ciprian Catana; Heike E Daldrup-Link; Bruce Rosen; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-22       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.